Results 101 to 110 of about 1,188 (167)

Pricing combination products: not how but who? [PDF]

Eur J Health Econ
Towse A, Briggs A, Steuten L.
europepmc   +1 more source

Onkologen sind für AMNOG-Evolution [PDF]

Im Focus Onkologie, 2012
openaire   +1 more source

From evidence to care delivery: Opportunities and risks in health and science policy. A position paper of the Association of the Scientific Medical Societies in Germany (AWMF). [PDF]

Ger Med Sci
Wörmann B, Kopp I, Nothacker M, Klar E, Sedlmayr M, Vogeser M, Schliephake H, Treede RD.   +7 more
europepmc   +1 more source

A review of 25 years of National Institute of Health and Care Excellence decision making. [PDF]

J Comp Eff Res
Zhang X, Tikhonovsky N, Ramagopalan SV.
europepmc   +1 more source

A comparative analysis of health technology assessment decision-making for cancer drugs in Germany and England. [PDF]

Front Public Health
He J, Wei H, Mo Q, Liu Y, Li X, Yang Y, Tian L.   +6 more
europepmc   +1 more source

Pharmaceutical price comparisons across the European Union and relative affordability in Cyprus [PDF]

, 2016
Petrou, Panagiotis, Vandoros, Sotiris
core   +1 more source

EU HTA Regulation and Joint Clinical Assessment-Threat or Opportunity? [PDF]

J Mark Access Health Policy
Schuster V.
europepmc   +1 more source

Evidence quality and uncertainties considered in appraisal documents of drugs for rare diseases in England and Germany: a data extraction protocol. [PDF]

BMJ Open
Wiedmann L, Nolte E, Cairns J.
europepmc   +1 more source

Abschätzung der Arzneimittelausgaben der Gesetzlichen Krankenversicherung 2014 und 2015: Gutachterliche Stellungnahme für den Verband forschender Arzneimittelhersteller e. V. (vfa) [PDF]

, 2013
Greß, Stefan, Wasem, Jürgen
core